U.S., April 7 -- ClinicalTrials.gov registry received information related to the study (NCT07512375) titled 'The Effectiveness of an ETP Programme in Myasthenia Gravis: a Proof-of-concept Study.' on March 30.
Brief Summary: CONTEXTE. Myasthenia gravis is a rare neuromuscular junction disorder affecting one in five thousand people (ORPHA 589). It is a chronic condition that progresses in episodes. Its severity varies, ranging from the invisible disability of fatigue to respiratory distress requiring intensive care. Currently, 270 patients with myasthenia gravis are being treated at Grenoble University Hospital in the Reference Centre for Rare Neuromuscular Diseases.
The impact of this disease on quality of life is significant, and medicati...